Form 4: Agenus CEO Garo Armen Takes Salary in Stock

Agenus Inc.'s Chairman and CEO, Garo H. Armen, elected to receive his salary in common stock, acquiring 3,983 shares at $3.71 each.

Summary

• Garo H. Armen, Chairman, CEO, and Principal Financial Officer of Agenus Inc., received 3,983 shares of common stock as payment for his salary for the pay period ending March 20, 2026.
• The shares were issued at a price of $3.71 per share, which was the closing price on March 20, 2026.
• This transaction was made at Dr. Armen's request and approved by the Agenus Inc. Compensation Committee, in lieu of cash.
• The shares are fully vested on the date of issuance and were issued under the Amended and Restated Agenus Inc. 2019 Equity Incentive Plan.
• Following this transaction, Dr. Armen directly holds 334,518 shares of common stock.
• He also indirectly holds 31,298 shares in IRA accounts and 28,950 shares through the Garo Armen 2020 2 Year AG GRAT and Pixie Partners.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, indicating management's confidence in Agenus's future by choosing equity over cash for compensation, aligning their interests with shareholders.

Positives

• Management's decision to take salary in stock demonstrates alignment with shareholder interests and confidence in the company's future.
• The shares are fully vested upon issuance, indicating immediate ownership.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash.

Industry Context

StockSavvy.ai notes that executives taking compensation in company stock is a common practice, particularly in growth-oriented sectors like biotechnology, as it aligns management incentives with long-term shareholder value creation. This move by Agenus's CEO signals confidence in the company's future prospects within the competitive biotech landscape.

Comparison to Industry Standards

• This practice is consistent with industry standards where executive compensation often includes equity components. For example, many biotech CEOs, such as those at Moderna or BioNTech, receive a significant portion of their compensation in stock or options to align their interests with the company's long-term success and innovation pipeline.
• While the specific amount is small, the principle of taking salary in stock is a strong signal of commitment, similar to how executives at companies like Regeneron Pharmaceuticals or Amgen often increase their holdings through various equity compensation plans.

Related Party Transactions

• The payment of salary in stock to the CEO, while a related party transaction, is a standard compensation practice approved by the Compensation Committee and disclosed as such.

Stakeholder Impact

• Shareholders: Potentially positive, as it signals management's confidence and alignment with shareholder interests.
• Employees: No direct impact on other employees is indicated.
• Customers/Suppliers/Creditors: No direct impact indicated.

Key Dates

Recommendation

While the CEO taking salary in stock is a positive signal of confidence and alignment, this specific transaction is a routine compensation event and relatively small in scale. It does not provide new fundamental information to warrant a change in investment thesis, thus a 'hold' recommendation is appropriate for existing investors, pending further operational or financial updates.

Keywords

Agenus, AGEN, Garo Armen, Insider Trading, Form 4, Stock Compensation, CEO Salary, Equity Incentive Plan, Director Stock Ownership, Biotechnology